Message :
Required fields
BRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company, today announced that its
® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Awards program conducted by
MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.
Upneeq
® provides patients and eye care providers with a safe and convenient non-surgical option to treat adults with acquired blepharoptosis (ptosis). The FDA-approved eye drop is the first and only therapeutic approved for the condition which previously required a surgical procedure. Upneeq
Digital Health Innovation Award: MedBridge
Best Hospital Technology Implementation: Hicuity Health
Best Health Network Technology Implementation: iMedX
Best Overall MedTech Software: NantHealth, Eviti Connect
Best Overall MedTech Company: Convey Health
Best Overall Digital Health Company: Doctor On Demand
Clinical and Health Administration
Best Compliance Solution: HOTB Software
Best Compliance Management Solution Provider: MedTrainer
Best Patient Registration & Scheduling Solution: Kyruus, ProviderMatch for Consumers
Best Computerized Decision Support Solution: Elsevier ClinicalPath
Best Overall Health Informatics Solution: Vim
Health Administration Innovation Award: Hospital IQ
Patient Engagement
Best Overall Patient Engagement Solution: Vocera Communications, Inc., Vocera Ease
Best Overall Patient Engagement Service: Greenphire Patient Convenience Suite: ClinCard & ConneX
Castle Biosciences Recognized for Skin Cancer Diagnostics Innovation in 2021 MedTech Breakthrough Awards Program
Share Article LOS ANGELES (PRWEB) May 06, 2021
MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market, today announced that Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, has been selected as the winner of the “Best New Technology Solution for Oncology” award in the fifth annual MedTech Breakthrough Awards program, recognizing Castle’s DecisionDx®-SCC and DecisionDx® DiffDx™-Melanoma solutions.
Castle Biosciences innovative genomic skin cancer testing technology harnesses information from individual patients’ tumor biology to inform management decisions and i